It has been shown in nine asthmatic patients that practolol, a selective cardiac beta-adrenergic antagonist, successfully blocks the unwanted tachycardia and palpitation following isoprenaline inhalation without hindering the beneficial bronchodilator action of the drug. Practolol is a useful adjunct to bronchodilator therapy in the management of bronchial asthma.
Attention has recently been directed to the possible lethal effect of aerosol sympathomimetic agents in the treatment of bronchial asthma (Speizer, Doll, Heaf and Strang, 1968) , death being attributed to an excitatory action on the heart. Animal studies indicate that practolol (I.C.I. 50,172, Eraldin) specifically blocks cardiac beta-adrenergic receptors, preventing arrhythmias or other alterations in cardiac function, but does not interfere with the bronchodilator actions of sympathetic amines (Dunlop and Shanks, 1968) . We have investigated the ability of I.C.I. 50,172 to protect the hearts of asthmatic patients from the excitatory action of sympathomimetic drugs.
METHODS
Nine patients aged 18 to 61 years with chronic, but partly reversible, airways obstruction were studied; none had significant cardiovascular disease (Table I) . All treatment was withheld on the night and morning before the investigation. The patien,t was connected to an electrocardiograph, for measurement of (Chamberlain, 1967) . The resultant tachycardia was estimated after 45 sec., and the mean of three F.E.V.1.o estimations was taken once more.
After 30 min. rest, when the control pulse rate and F.E.V.1.o had returned to a steady value, the entire procedure was repeated. On this occasion a slow intravenous injection of 20 mg. of I.C.I. 50,172 was given prior to the isoprenaline inhalation and the change in pulse rate and mean F.E.V.1.o was noted. The effect of the inhalation of isoprenaline on the pulse rate and F.E.V.1.o was then measured as before. To avoid the effort tachycardia produced during estimation of F.E.V.1.o, the pulse rates were always measured first. Symptomatic changes, such as palpitations and headache, and all cardiac arrhythmias were noted.
RESULTS
The variations in pulse rate and F.E.V.1.,, when an isoprenaline aerosol is inhaled with and without intravenous I.C.I. 50,172 are shown in Tables II  and III . The statistical significance of these results is also tabulated. I.C.I. 50,172 significantly slows th! resting pulse rate and profoundly depresses isoprenaline-induced tachycardia. The mean increase in pulse rate after isoprenaline in patients who had received I.C.I. 50,172 was only 6 beats/ min. compared with 26 without I.C.I. 50,172. In spite of the half-hour rest, the initial F-Ey.I.0 was Selective cardiac sympathetic blockade as an adjunct to bronchodilator therapy Ahlquist's (1948) classification of adrenergic receptors. Recently, a similar compound, 4-(2-hydroxy-3-isopropyl-aminopropoxy) acetanilide, I.C.I. 50,172, has been discovered which is an adrenergic receptor antagonist with a much greater degree of specificity for cardiac than for other beta-receptors. The beta-adrenergic sites of the smooth muscle of the bronchi and trachea are relatively unaffected by this drug. Animal experiments have shown that I.C.I. 50,172 blocks the action of both adrenaline, the natural sympathetic transmitter, and isoprenaline, which is a synthetic beta-sympathetic stimulating agent.
In the present study it was found that infusion of I.C.I. 50,172 produced significant slowing of the resting pulse rate (from a mean of 101 per minute to a mean of 83 per minute), contrary to the finding in anaesthetized cats and dogs, which show little change in heart rate with infusions of I.C.I. 50,172 (Dunlop and Shanks, 1968) , and the study of Brick, Hutchison, McDevitt, Roddie, and Shanks (1968) who found that I.C.I. 50,172 administered to healthy volunteers in doses of 5 to 20 mg. produced little change in heart rate. This difference may be due to increased sympathetic tone in patients with airways obstruction. However, Gibson and Sowton (1968) demonstrated a 16% reduction in pulse rate after intravenous I.C.I. 50,172 during submaximal exercise in healthy volunteers, and similar findings have been reported by Shinelbourne, Fleming, and Hamer (1968) in hypertensive and ischaemic heart disease. Sowton, Balcon, Cross, and Frick (1968) showed a reduction in resting heart rate after I.C.I. 50,172 in ischaemic heart disease and suggest that resting sympathetic activity may be increased in these patients.
We are able to demonstrate a profound depression of isoprenaline-induced tachycardia with I.C.I. 50,172 and this confirms results obtained in anaesthetized animals (Dunlop and Shanks, 1968) and healthy volunteers (Brick et al., 1968) . The marked reduction in palpitation in our series is probably related to the blockage of the inotropic effect in addition to the chronotropic effect of isoprenaline (Dunlop and Shanks, 1968 (Dunlop and Shanks, 1968) .
The clear-cut reduction in airways resistance after I.C.I. 50, 172 indicates that there is some bronchial adrenergic blocking effect, and suggests caution in the use of this drug in patients with Raymond Powles, Elliot Shinebourne, and John Hamer airways obstruction unless it is promptly followed by administration of a potent bronchodilator. These findings suggest that the effect of I.C.I. 50,172 on bronchial smooth muscle is greater in patients with airways obstruction than in experimental animals. Dunlop and Shanks (1968) 
